Skip to main content
OpenTrials
Completed

NCT Number: NCT01209416

The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin

This study will investigate the non-growth-hormone-dependent metabolic effects of the hormone Ghrelin in growth hormone deficient subjects by examining the insulin tolerance as well as signal proteins in fat and muscle biopsies.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Ghrelin is a relatively 'new' hormone that is produced in the stomach and to a lesser extend in the hypothalamus of the brain. The actions of ghrelin are diverse and includes stimulation of the appetite center of the brain and the release of growth hormone. We have for the first time shown that ghrelin also stimulates the metabolism of fatty acids and induces insulin resistance in skeletal muscle. These effects have we confirmed in growth hormone deficient subjects on a stabile substitution treatment with growth hormone and hydrocortisone. With these subjects we can investigate the effects of ghrelin that are independent of growth hormone. The present study is a continuation of these findings, as we wish to investigate whether the insulin resistance effect of ghrelin is dependent of the concomitant metabolism of fatty acids. This is possible by administration of the niacin acid antagonist Acipimox, that blocks the fatty acid metabolism reversibly. We have applied this experimental principle in other settings with success.

Knowledge of the effects of ghrelin in general can in shot-sight as well as in long-sight have great importance for the understanding of growth disorders from overweight and type 2 diabetes to malnutrition and eating disorders.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • males with hypopituitarism in regard to growth hormone and ACTH in stabile treatment regime
  • age 18-65
  • BMI 20-35

Exclusion criteria

  • abuse of alcohol
  • malign disease
  • medication other than that expected for hypopituitarism
  • known disease other than hypopituitarism
  • participation in isotope investigations the last 6 months

Treatment and study plan

Acipimox

Drug

Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day

Other names: Tablet Olbetam 250 mg

Ghrelin

Drug

Ghrelin infusion 4.2 ng/kg/min throughout the investigation day

Placebo

Other

placebo tablets or saline infusion

Other names: Placebo tablets, Saline infusion

Primary outcomes

  1. Effects of ghrelin during basal and hyperinsulinemic conditions

    Time frame: 5 hours investigation day

    Growth hormone deficient patient investigated with ghrelin infusion and pharmacological antilipolysis (Acipimox) in a randomized cross-over study with 4 study days. During each visit signal proteins in muscle and fat biopsies are investigated with PCR, wester blot and activity assays for ghrelin, growth hormone and insulin. Further is glucose metabolism investigated in basal conditions and during hyperinsulinemic euglycemic clamp.

  2. Effects of ghrelin during basal and hyperinsulinemic conditions

    Time frame: 5 hours investigation day

    Effects of ghrelin on heart rate variability

  3. Effects of ghrelin during basal and hyperinsulinemic conditions

    Time frame: 5 hours investigation day

    Effects of ghrelin on thirst, fluid intake, urine production and natriuresis

Sponsors and collaborators

Lead sponsor

University of Aarhus

Other

Registry information

Important dates

Study start
2012
Primary completion
2014
Study completion
2015
First posted
Sep 27, 2010
Registry last updated
Oct 30, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.